SGR-2921
Investigators interested in participating in this clinical program, please click below.
Investigational CDC7 inhibitor
Target
CDC7
Program Type
Proprietary, small molecule
Indication
Hematologic malignancies and solid tumors
Stage
Phase 1 clinical development
SGR-2921 is a cell division cycle 7-related protein kinase (CDC7) inhibitor
CDC7 is a protein kinase that plays a critical role in cell cycle regulation and DNA replication. Elevated replication stress is a common feature of many cancers with high cell proliferation. CDC7 has been shown to activate key components of the replication stress response, helping to mitigate cancer cells’ DNA damage and promote genomic stability. Inhibiting CDC7 in cancer cells results in an impaired response to replication stress, leading to accumulation of DNA damage and cell death. External clinical studies are showing promise of CDC7 as a therapeutic target in oncology.
Our Approach
We leveraged our physics-based computational platform to design novel, potent CDC7 inhibitors with high selectivity, potency, ligand efficiency, and other important drug-like properties. Multiple acute myeloid leukemia (AML) models have confirmed the strong anti-tumor activity of SGR-2921, both as a monotherapy and in combination with standard of care agents. In addition, preclinical data demonstrate anti-tumor activity of SGR-2921 in tumor models resistant to standard of care agents.
SGR-2921 is currently in clinical development in patients with AML or myelodysplastic syndromes.
Clinical trial information
Patient trial
A Phase 1 clinical trial of SGR-2921 is ongoing to evaluate safety and tolerability and to determine the maximum tolerated dose and/or recommended dose in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Expanded access statement
Schrödinger does not currently have an approved access program for our investigational products. We encourage patients to speak with their physicians about treatment options that may be right for them.
Presentations
Poster Presentation
SGR-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease
Presented at: American Society of Hematology 2023 Annual Meeting
Poster Presentation
Inhibition of CDC7 with SGR-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents
Presented at: American Society of Hematology 2022 Annual Meeting
Services
Explore resources for patients and physicians.
Investigator resources
Investigators interested in participating in this clinical program, please click below.